Nabriva Therapeutics plc Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q1 2017 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Nabriva Therapeutics plc quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q1 2017 to Q2 2023.
  • Nabriva Therapeutics plc Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending June 30, 2023 was $2.24M, a 75.6% decline year-over-year.
  • Nabriva Therapeutics plc Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending June 30, 2023 was $29.6M, a 16.4% decline year-over-year.
  • Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $36.9M, a 27.8% increase from 2021.
  • Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $28.9M, a 475% increase from 2020.
  • Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2020 was $5.03M, a 47% decline from 2019.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $29.6M $2.24M -$6.95M -75.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-10-19
Q1 2023 $36.5M $7.59M -$430K -5.36% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-22
Q4 2022 $36.9M $10.6M +$1.31M +14.1% Oct 1, 2022 Dec 31, 2022 10-K 2023-04-17
Q3 2022 $35.6M $9.15M +$291K +3.28% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $35.3M $9.19M +$948K +11.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-19
Q1 2022 $34.4M $8.02M +$5.49M +217% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-22
Q4 2021 $28.9M $9.26M +$6.8M +276% Oct 1, 2021 Dec 31, 2021 10-K 2023-04-17
Q3 2021 $22.1M $8.86M +$7.57M +586% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $14.5M $8.24M +$7.76M +1593% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $6.77M $2.53M +$1.74M +221% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $5.03M $2.46M +$2.13M +639% Oct 1, 2020 Dec 31, 2020 10-K 2023-04-17
Q3 2020 $2.9M $1.29M -$5.63M -81.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $8.53M $487K -$38K -7.24% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $8.57M $789K -$914K -53.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $9.48M $333K -$464K -58.2% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 $9.95M $6.92M +$6.46M +1401% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $3.49M $525K -$322K -38% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $3.81M $1.7M -$5.85M -77.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $9.66M $797K -$325K -29% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $9.98M $461K -$1.01M -68.6% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 $11M $847K -$204K -19.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 $11.2M $7.55M +$5.87M +350% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 $5.32M $1.12M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 $1.47M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 $1.05M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 $1.68M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.